CA2769359C - Nitroimidazooxazines and their uses in anti-tubercular therapy - Google Patents

Nitroimidazooxazines and their uses in anti-tubercular therapy Download PDF

Info

Publication number
CA2769359C
CA2769359C CA2769359A CA2769359A CA2769359C CA 2769359 C CA2769359 C CA 2769359C CA 2769359 A CA2769359 A CA 2769359A CA 2769359 A CA2769359 A CA 2769359A CA 2769359 C CA2769359 C CA 2769359C
Authority
CA
Canada
Prior art keywords
nitro
dihydro
imidazo
oxazine
trifluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2769359A
Other languages
English (en)
French (fr)
Other versions
CA2769359A1 (en
Inventor
William Alexander Denny
Andrew M. Thompson
Adrian Blaser
Zhenkun Ma
Brian Desmond Palmer
Hamish Scott Sutherland
Iveta Kmentova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TB Alliance
Original Assignee
TB Alliance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TB Alliance filed Critical TB Alliance
Publication of CA2769359A1 publication Critical patent/CA2769359A1/en
Application granted granted Critical
Publication of CA2769359C publication Critical patent/CA2769359C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2769359A 2009-07-31 2010-07-30 Nitroimidazooxazines and their uses in anti-tubercular therapy Expired - Fee Related CA2769359C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23039609P 2009-07-31 2009-07-31
US61/230,396 2009-07-31
PCT/US2010/043906 WO2011014774A1 (en) 2009-07-31 2010-07-30 Nitroimidazooxazines and their uses in anti-tubercular therapy

Publications (2)

Publication Number Publication Date
CA2769359A1 CA2769359A1 (en) 2011-02-03
CA2769359C true CA2769359C (en) 2017-03-07

Family

ID=42937154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2769359A Expired - Fee Related CA2769359C (en) 2009-07-31 2010-07-30 Nitroimidazooxazines and their uses in anti-tubercular therapy

Country Status (12)

Country Link
EP (1) EP2459571B1 (enExample)
JP (1) JP5781072B2 (enExample)
KR (1) KR101746482B1 (enExample)
CN (1) CN102753558B (enExample)
AU (1) AU2010278777B2 (enExample)
BR (1) BR112012002278A2 (enExample)
CA (1) CA2769359C (enExample)
ES (1) ES2536997T3 (enExample)
IN (1) IN2012DN01414A (enExample)
NZ (1) NZ598121A (enExample)
RU (1) RU2542988C2 (enExample)
WO (1) WO2011014774A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
CN104059082B (zh) * 2013-03-21 2016-08-03 苏州迈泰生物技术有限公司 硝基咪唑杂环类化合物及其在制备治疗结核病药物中的应用
KR101682356B1 (ko) 2014-11-04 2016-12-06 한국화학연구원 이미다조 옥사진 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학이성질체 및 이를 유효성분으로 함유하는 약제학적 조성물
EP3252059A4 (en) 2015-01-29 2018-07-11 Medshine Discovery Inc. Anti-pulmonary tuberculosis nitroimidazole derivative
CN108047248A (zh) * 2018-02-12 2018-05-18 丹诺医药(苏州）有限公司 噁唑烷酮-硝基咪唑类偶联分子的应用
CN113527331B (zh) * 2020-04-17 2024-05-28 南京长澳医药科技有限公司 硝基咪唑类衍生物及其制备方法和用途
CN113355439A (zh) * 2021-06-07 2021-09-07 深圳市普瑞康生物技术有限公司 一种结核分枝杆菌潜伏感染及发病的新型组合检测方法
CN114469946B (zh) * 2022-02-24 2023-10-24 首都医科大学附属北京胸科医院 德拉马尼作为cxcl10抑制剂的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280914B6 (sk) 1994-03-08 2000-09-12 American Home Products Corporation Tiazolidíndiónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US5668127A (en) * 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
US6087358A (en) * 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
AR041198A1 (es) * 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
CN100497345C (zh) * 2003-10-31 2009-06-10 大塚制药株式会社 治疗结核病的2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
DE602005004040T2 (de) 2004-01-16 2008-12-11 Sumitomo Chemical Co., Ltd. Malononitrilverbindungen als Pestizide
TWI300409B (en) * 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
WO2006043121A1 (en) * 2004-10-20 2006-04-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
KR20080038369A (ko) * 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
JP2009521464A (ja) * 2005-12-23 2009-06-04 ノバルティス アクチエンゲゼルシャフト ニトロイミダゾール化合物
CN101965353B (zh) * 2008-03-26 2014-12-17 丹诺医药(苏州）有限公司 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类

Also Published As

Publication number Publication date
JP5781072B2 (ja) 2015-09-16
KR20120084713A (ko) 2012-07-30
JP2013500996A (ja) 2013-01-10
AU2010278777A1 (en) 2012-03-01
WO2011014774A1 (en) 2011-02-03
RU2012107176A (ru) 2013-09-10
EP2459571A1 (en) 2012-06-06
IN2012DN01414A (enExample) 2015-06-05
BR112012002278A2 (pt) 2020-09-15
EP2459571B1 (en) 2015-03-11
CA2769359A1 (en) 2011-02-03
KR101746482B1 (ko) 2017-06-27
RU2542988C2 (ru) 2015-02-27
AU2010278777B2 (en) 2015-05-07
NZ598121A (en) 2013-04-26
CN102753558B (zh) 2014-10-15
CN102753558A (zh) 2012-10-24
ES2536997T3 (es) 2015-06-01

Similar Documents

Publication Publication Date Title
AU2010278777B2 (en) Nitroimidazooxazines and their uses in anti-tubercular therapy
EP4028403B1 (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
JP6789995B2 (ja) Ｎｒｆ２レギュレーター
EP2970120B1 (en) Novel pyrimidine and pyridine compounds and their usage
US8293734B2 (en) Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
EA029091B1 (ru) Производные бензимидазола в качестве ингибиторов бромодомена
CN114401968A (zh) 新颖杂环单酰基甘油脂肪酶(magl)抑制剂
EA030404B1 (ru) Модуляторы flap
US9198913B2 (en) Nitroimidazooxazines and their uses in anti-tubercular therapy
RU2662157C2 (ru) 2-пиридоновое соединение
EP4543870A1 (en) New heterocyclic-carbonyl-cyclic compounds as magl inhibitors
KR20240135076A (ko) 니코틴아미드 ripk1 억제제
JPH0673052A (ja) ベンゾフラン誘導体
HK40062310A (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
RU2793936C2 (ru) Борсодержащие ингибиторы pde4

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150707

MKLA Lapsed

Effective date: 20200831